All the news Showing 10 of 136 articles.Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection Liz Highleyman / 26 July 2017 AbbVie's new pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C co-infection in the EXPEDITION-2 study, according to a presentation on Monday at the 9th International AIDS Society ... Six-question risk score can identify HIV-positive gay men needing testing for acute hepatitis C Roger Pebody / 13 June 2017 Six questions can identify HIV-positive gay men who are at elevated risk of having acute (recent) hepatitis C infection and who would benefit from further testing, according to a paper ... Co-infection with HCV increases cancer risk for people with HIV Michael Carter / 28 March 2017 People with HIV and hepatitis C virus (HCV) co-infection have an increased risk of non-AIDS-defining cancers compared to people with HIV mono-infection, investigators from Spain report in the online edition of AIDS. Even ... Two-thirds of people with HIV/HCV co-infection in Southeast Asia in need of HCV therapy Michael Carter / 15 March 2017 Almost two-thirds of people with HIV/hepatitis C virus (HCV) co-infection in Asia are in need of HCV therapy with a fifth of people having cirrhosis, investigators report in the Journal of Viral ... Glecaprevir/pibrentasvir for hepatitis C can be safely administered with common antiretrovirals Liz Highleyman / 13 March 2017 AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering a new option for people with HIV/hepatitis C ... DAA therapy cures most people with HIV/HCV co-infection with decompensated cirrhosis or liver transplants Liz Highleyman / 07 March 2017 People with HIV/hepatitis C virus (HCV) co-infection with liver cirrhosis or liver failure, and those who received liver transplants, saw high rates of sustained virological response using interferon-free direct-acting antiviral (DAA) therapy for ... Are people with HIV and HCV co-infection who are cured of hepatitis C with DAAs at increased risk for liver cancer? Liz Highleyman / 27 February 2017 People with HIV and hepatitis C virus (HCV) co-infection who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular ... New hepatitis C infections among HIV-positive gay men drop by half after direct-acting antiviral roll-out in Netherlands Liz Highleyman / 17 February 2017 A little more than a year after the Netherlands instituted a policy allowing unrestricted access to direct-acting antivirals for the treatment of hepatitis C, researchers have already seen a dramatic decline in acute ... High hepatitis C prevalence seen in Amsterdam PrEP study participants Gus Cairns / 06 February 2017 Researchers from the Dutch pre-exposure prophylaxis (PrEP) demonstration study, AmPrEP, have found an unexpectedly high rate of hepatitis C virus (HCV) infection in participants tested for it at baseline.The HCV ... Sofosbuvir/ledipasvir is effective for people with HIV/HCV co-infection in real-world clinical practice Liz Highleyman / 28 November 2016 The sofosbuvir/ledipasvir (Harvoni) co-formulation used in real-world clinical practice produced good sustained virological response rates similar to those seen in clinical trials for HIV-positive people with hepatitis C co-infection, according to a pooled ... ← Prev1...34567...14Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive